"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
In case of accidental overdosage, as evidenced by excessive blood pressure elevation, reduce rate of administration or temporarily discontinue DOPAMINE (dopamine hydrochloride) until patient's condition stabilizes. Since the duration of action of DOPAMINE (dopamine hydrochloride) is quite short, no additional remedial measures are usually necessary. If these measures fail to stabilize the patient's condition, use of the short-acting alpha adrenergic blocking agent, phentolamine, should be considered.
DOPAMINE (dopamine hydrochloride) should not be used in patients with pheochromocytoma.
DOPAMINE (dopamine hydrochloride) should not be administered in the presence of uncorrected tachyarrhythmias or ventricular fibrillation.
Last reviewed on RxList: 10/4/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Dopamine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.